ReviewCancers2022
Diagnosis and Management of Porocarcinoma.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- S1 guideline sweat gland carcinoma.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Guideline
- Porocarcinoma: Clinical and Histological Features, Immunohistochemistry and Outcomes: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Hidden Malignancy: Predominantly InSitu Porocarcinoma Arising in a Poroma.The American Journal of dermatopathology · 2026Article
- RNA-Sequencing Reveals Two Subgroups of Eccrine Porocarcinomas and Poromas.Journal of cellular and molecular medicine · 2026Article
- [Eccrine porocarcinoma on the dorsum of the foot: case report of a rare tumor]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2026Article
- Aggressive multifocal recurrent porocarcinoma of the face: a case report and review of the literature.Journal of surgical case reports · 2026Article
- Epidemiology, treatment patterns, and survival outcomes of porocarcinoma: A population-based analysis.Medicine · 2026Article
- Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- A Case of Mohs Micrographic Surgery for Facial Porocarcinoma in an Adolescent and Literature Review.Case reports in oncological medicine · 2026Article
- Minor trauma-induced eccrine porocarcinoma of the toe in a patient on long-term carbamazepine: a case report and literature review.Frontiers in oncology · 2026Article
- Stable Disease Achieved with Sequential Immunochemotherapy and Anti-Angiogenic TKI in Recurrent Metastatic Hidradenocarcinoma: A Case Report and Literature Review.Oncology research · 2026Review
- Eccrine carcinomas and homologous recombination repair cancer predisposition genes: A case series.JAAD case reports · 2025Article
- Article
- Elucidating Cytomorphological Features of Eccrine Porocarcinoma on The Forehead Presenting Without Pre-existing Poroma in an Adult Male: A Rarity Unveiled with a Comprehensive Review of Literature.Indian journal of surgical oncology · 2025Review
- Eccrine malignancies in nevus sebaceus: Case presentation and review of the literature.JAAD case reports · 2025Article
- A woman with mycosis fungoides, vitiligo, and a new hand nodule.International journal of dermatology · 2025Article
- Whole-exome sequencing identifies distinct genomic aberrations in eccrine porocarcinomas and poromas.Orphanet journal of rare diseases · 2025Article
- Multiline treatment of primary cutaneous adenoid cystic carcinoma with multiple metastases: a case report and literature review.Frontiers in oncology · 2025Article
- Diagnosis and Management of Malignant Epithelial Nail Unit Tumors.Diagnostics (Basel, Switzerland) · 2024Review
- Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab.JAAD case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eccrine porocarcinoma, also known as porocarcinoma (PC) and malignant eccrine poroma, is very rare and is known to arise from the cutaneous intraepidermal ducts of the sweat glands. Its etiology is not well understood; however, some studies suggest that PC tumors originate from benign eccrine poroma. Recently, several gene alterations have been reported in PC that can reveal mechanisms of the oncogenic process. Since the clinical and histopathological findings of PC are variable, PC is difficult to diagnose precisely, especially when the histology resembles that of cutaneous squamous cell carcinoma or poroma. Immunohistochemical staining with carcinoembryonic antigen and epithelial membrane antigen may help to distinguish PC from other tumors. The standard treatment for local PC is wide local excision. The prognosis of patients with metastatic PC is poor, with mortality rates of approximately 60-70%. The efficacy of radiation and chemotherapy for metastatic PC is limited; however, immunotherapy with pembrolizumab, a programmed cell death protein 1 inhibitor, could be a promising treatment. This review focuses on the history, pathogenesis, pathological features, diagnosis, and treatment of eccrine porocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.